The Cost-Effectiveness Of The Manchester ‘Lung Health Checks’, A Community-Based Lung Cancer Low-Dose CT Screening Pilot by Hinde, Sebastian et al.
This is a repository copy of The Cost-Effectiveness Of The Manchester ‘Lung Health 
Checks’, A Community-Based Lung Cancer Low-Dose CT Screening Pilot.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/138271/
Version: Accepted Version
Article:
Hinde, Sebastian orcid.org/0000-0002-7117-4142, Crilly, Tessa, Balata, Haval et al. (7 
more authors) (2018) The Cost-Effectiveness Of The Manchester ‘Lung Health Checks’, A 
Community-Based Lung Cancer Low-Dose CT Screening Pilot. Lung Cancer. pp. 119-124.
ISSN 0169-5002 
https://doi.org/10.1016/j.lungcan.2018.10.029
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Accepted Manuscript
Title: The Cost-Effectiveness Of The Manchester ‘Lung
Health Checks’, A Community-Based Lung Cancer
Low-Dose CT Screening Pilot
Authors: Sebastian Hinde, Tessa Crilly, Haval Balata, Rachel
Bartlett, John Crilly, Phil Barber, Anthony Threlfall, Janet
Tonge, Richard Booton, Phil Crosbie
PII: S0169-5002(18)30627-5
DOI: https://doi.org/10.1016/j.lungcan.2018.10.029
Reference: LUNG 5826
To appear in: Lung Cancer
Received date: 1 August 2018
Revised date: 16 October 2018
Accepted date: 31 October 2018
Please cite this article as: Hinde S, Crilly T, Balata H, Bartlett R, Crilly J, Barber P,
Threlfall A, Tonge J, Booton R, Crosbie P, The Cost-Effectiveness Of The Manchester
‘Lung Health Checks’, A Community-Based Lung Cancer Low-Dose CT Screening
Pilot, Lung Cancer (2018), https://doi.org/10.1016/j.lungcan.2018.10.029
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
The Cost-Effectiveness Of The Manchester  ?Lung ,ĞĂůƚŚŚĞĐŬƐ ?, A Community-Based Lung Cancer 
Low-Dose CT Screening Pilot. 
 
Corresponding Author: Mr. Sebastian Hinde, BSc, MSc 
Corresponding Author's Institution: University of York 
First Author: Sebastian Hinde, BSc, MSc 
Order of Authors: Sebastian Hinde, BSc, MSc; Tessa Crilly; Haval Balata; 
Rachel Bartlett; John Crilly; Phil Barber; Anthony Threlfall; Janet 
Tonge; Richard Booton; Phil Crosbie 
 
Highlights 
x The use of CT to screen for lung cancer remains hotly debated 
x We explored the cost-effectiveness of screening in a targeted community setting 
x By updating evaluation methodology used in UKLS we ensure consistency of findings  
x We find the use of community screening to be cost-effective  
 
Abstract  
Background 
Previous evaluations of low-dose CT (LDCT) lung cancer screening programmes have taken very 
different approaches in the design of the informative trials and the methods applied to determine 
cost-effectiveness.  Therefore, it has not been possible to determine if differences in cost-
effectiveness are due to different screening approaches or the evaluation methodology. This study 
reports the findings of an evaluation of the first round of a community-based, LDCT screening pilot 
Manchester, applying previously published methodology to ensure consistency. 
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Methods  
Using the economic evaluation method reported in the UKLS trial, applying Manchester specific 
evidence where possible, we estimate the cost-effectiveness of LDCT for lung cancer.  Estimates of the 
total costs and quality adjusted life years (QALYs) were calculated. 
Results 
The Manchester programme cost £663,076, diagnosed 42 patients with lung cancer resulting in a gain 
in population health of 88.13 discounted life years, equivalent to 65.85 QALYs.  This implied an 
incremental cost-effectiveness ratio of £10,069/QALY. 
Conclusions  
We found the Manchester programme to be a cost-effective use of limited NHS resources.  The 
findings suggest that further research is now needed not as to whether LDCT screening is cost-
effective but under what conditions can it improve patient health by the most while remaining cost-
effective.  
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Introduction 
In recent years the debate over the value of screening for lung cancer has intensified with the 
conclusion of a number of high cost randomised trials from around the world, including NLST, UKLS, 
and NELSON.[1-3]  Based largely on the results of NLST the US Preventive Services Task Force (USPSTF) 
recommended screening with LDCT in 2013.[4]  This has been followed by similar statements from 
other countries including the Chief Executive of the NHS in the UK, Simon Stevens, in 2017 [5] and the 
recent European position statement.[6]  ,ŽǁĞǀĞƌ ?ĨŽƌŵĂůůǇ^ŝŵŽŶ^ƚĞǀĞŶƐ ?ƐƐƚĂƚĞŵĞŶƚdiffers from 
the views currently held by the UK National Screening Committee (NSC) ǁŚŽ ?Ɛ most recent review in 
2006 concluded such screening was not recommended.[7]  Whilst another review is due upon the 
publication of the NELSON trial, the debate over the worth of a screening programme is far from 
settled. 
The intrinsic appeal of such screening programmes is clear, with lung cancer causing around 35,600 
deaths every year in the UK[8], a level that has stayed stubbornly high. Despite knowledge of the risk 
factors the majority of patients still present with advanced disease[5] when curative treatment 
options are limited.   
It has been argued that despite the evidence of mortality benefit shown in NLST continued caution is 
required due to the issues associated with high false positive rates typically reported in screening 
trials.[9]  Such concerns around the relative merits of the benefits of an intervention compared to its 
harms can be addressed through economic evaluation, which explicitly employs validated methods to 
consider the health and cost implications of all affected parties in a single statement of cost-
effectiveness.  Furthermore, the recent study by Field et al.[10] looking at which areas of the screening 
debate were yet to be fully resolved highlighted cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐ ĂƐ  ‘ĂŵďĞƌ ? meaning  ‘requiring 
further research ?, highlighting a limited pool of cost-effectiveness analyses. 
This paper seeks to expand on the existing pool of cost-effectiveness studies by evaluating the results 
of the recently conducted community-based lung cancer screening pilot in deprived areas of 
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Manchester.[11]  In doing so it also provides evidence on ƚŚĞ ŽŶůǇ  ‘ƌĞĚ ? ĐĂƚĞŐŽƌǇ ŽĨ ƚŚĞ ƚǁĞůǀĞ
considered by Field et al., that of the recruitment of patients in  ‘hard-to-reach ? deprived communities, 
addressing the role of community based lung health checks and the use of mobile LDCT units.    
 
The Pilot Programme Being Evaluated 
dŚĞDĂŶĐŚĞƐƚĞƌ ‘>ƵŶŐ,ĞĂůƚŚŚĞĐŬ ? (LHC) pilot programme was designed to address both the health 
burden associated with lung cancer but also to reduce the barriers to participation in those at greatest 
risk by reducing travel time and increasing convenience.[11]  Ever smokers aged 55 to 74 registered 
at one of the participating GP practices (14 across Manchester) were invited to have a LHC at 
convenient community venues, where respiratory symptoms, spirometry and 6-year lung cancer risk 
(using PLCOM2012) were assessed.  Those found to have a 6-ǇĞĂƌůƵŶŐĐĂŶĐĞƌƌŝƐŬŽĨA? ? ? ? ?A?were eligible 
for and offered LDCT screening. This consisted of annual screening over two rounds including an 
immediate scan in a co-located mobile CT scanner.  
Of 16,402 invitations to participate, 2,541 LHCs were conducted, with 1,384 going on to have a LDCT.  
The pilot diagnosed 42 patients with lung cancer with 63% stage I, 17.4% stage II, 8.7% stage III, and 
10.9% stage IV.  Using historic controls a statistically significant stage shift was demonstrated 
compared to those with symptomatic presentation. 
Methodological approach 
A major limitation of the existing literature on the cost-effectiveness of a lung cancer screening 
programme is the variation in methodology used.  As an example, the cost-effectiveness studies linked 
to two of the large trials, NLST and UKLS, reported very different base-case results $81,000/ Quality 
Adjusted Life Year (QALY) (roughly £60,000 in 2018 values)[12] and £8,466/QALY.[2]  However, the 
extent to which this is the result of different programme designs or the impact of different evaluative 
methodologies is unclear due to different methodological approaches being used for the evaluations.  
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These are just two of the large array of literature on cost-effectiveness of lung cancer screening, all 
facing similar issues of a lack of comparability of methods. [13-18] 
To ensure comparability of the evaluation of the Manchester LHC pilot with other trials, the economic 
evaluation conducted for the UKLS trial analysis was reconstructed.  The UKLS method was chosen for 
a number of reasons including, primarily, its relevance to a UK setting but also the accessibility of the 
methods and validity as a reference point since its independence from the trial, reducing the risk of 
inherent bias in the approach and assumptions used.[19]   
The ŵĞƚŚŽĚŽůŽŐŝĐĂůĂƉƉƌŽĂĐŚ ?ŚĞƌĞĂĨƚĞƌ ƚŚĞ  ‘UKLS ŵĞƚŚŽĚ ? ?ĂƐǁŝƚŚĂŶǇĞǀĂůƵĂƚŝŽŶĂƉƉƌŽĂĐŚ ?ŚĂƐ
limitations which it is important to be aware of. Most notably these include the assumption driven 
estimation of lead time, the simplistic approach to quality of life adjustment, and the assumption 
linking earlier stage diagnosis with gains in survival as a result of screening compared to symptomatic 
presentation.  These are considered in more detail during the presentation of the model in the next 
section and are explored through sensitivity analysis in this study. 
Methods 
As details of the UKLS method are published extensively elsewhere [2, 19] this section is limited to a 
brief overview of the methods, with a focus on the differences in the parameter values used in this 
study compared to UKLS. 
The core approach 
The UKLS method takes a two part approach to the estimation of the costs and benefits associated 
with a screening programme, defining an algebraic formula to determine the total additional cost 
implications alongside a life table approach to estimating the impact of the programme on the 
expected years of life lived by each patient.  The estimated life years (LY) are then adjusted by an 
estimate of the quality of life the affected patients would be expected to have to give an estimate of 
the QALYs. 
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The estimation of incremental total cost seeks to combine the three main cost factors: the cost of 
conducting the screening programme, the cost implications of diagnosing and treating a true positive, 
and those of diagnosing a false positive.  These are combined using the function: 
CS + NP (ITP+T) + N& ? IFP 
Where: 
CS  ? the cost of conducting the screening programme 
NP  ? the number of true positives in the cohort 
I  ? the cost of the investigation of a positive screen result which is considered separately for true 
positives, ITP, and false positives, IFP.  
T  ? the net additional cost of treating a screen detected cancer, compared to a symptomatic 
presentation (this takes into account the lead time to presentation) 
NF  ? The number of false positives picked up by the programme 
The assumption is therefore made that all true negatives and false negatives imply no change in the 
cost implications compared to a scenario where no screening programmes were available beyond the 
cost of the screen itself.  This is certainly accurate for true negatives, who would not be expected to 
change how they interacted with the NHS, but it could be argued that false negatives (i.e. those with 
cancer who are not identified by the screen) are less likely to seek care for suspected lung cancer at a 
later date.  However, it is not possible to incorporate an estimate of this, as both the rate of false 
negatives and the change in their actions as a result are largely unknown in this setting.   
In keeping with best practice, all costs and benefits are discounted at a rate of 3.5% per year, and a 
NHS and PSS perspective is taken on costs, and population health, measured in terms of QALYs for the 
benefits.[20] 
Parameter estimates 
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Costs 
As discussed above in order to estimate the additional cost implication of screening we need to know: 
the cost of conducting the screening programme, the number and cost implications of true positives, 
and the number and cost implications of false positives.   
The costs of conducting the screening programme are reported in Table 1, where all frequencies and 
unit costs have been directly observed from the Manchester LHC pilot and therefore represent  ‘real 
world ? estimates.  The costs exclude the non-recurrent project costs associated with setting up the 
pilot (estimated at £315,000, funding a programme office that was tasked with exploring evidence 
and designing the pilot rather than directly running a screening service) and, as noted elsewhere, are 
limited to the first 3 month follow-up scan. 
[Table 1 here] 
 
The cost of treating true positive and false positive results combines the observed number of each of 
these from the programme (42 true positives, 39 false positives) with an estimate of the unit cost 
incorporating diagnostics to confirm or contradict the initial scan and the subsequent treatment for 
true positives.  The cost of diagnostic workup after the CT was estimated using frequencies of activities 
reported by the pilot, combined with unit cost estimates provided by University Hospital of South 
Manchester (UHSM) are reported in Table 2.  It should be noted that the unit costs differ from National 
NHS Reference Costs as they represent the local costs rather than national averages.  Estimates 
suggest that the use of the NHS Reference Costs (2015/16)[21] would result in the total cost of the 
programme to be £12,000 lower.   
[Table 2 here] 
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To estimate the additional treatment costs associated with the true positive diagnoses it was 
necessary to estimate both the cost profile for the true positive patients given they were diagnosed 
earlier (i.e. due to the screen), denoted CCT, compared to had they been otherwise been diagnosed 
later, CSP.  Given the lack of long-term follow up in the pilot both costs are based on estimated 
treatment pathways.  Both are estimated by applying stage and intervention specific unit cost 
estimates from CRUK[22] alongside estimates of the stage distribution, either from the pilot (to inform 
CCT) or from an estimate of the stage distribution of the population without the programme, here using 
ONS data, to inform CSP.  CSP is additionally adjusted for discounting, as the costs will occur at a later 
date.  The average time to symptomatic presentation used to inform the discount rate is estimated by 
a weighting of the stage-specific lead times reported later in this section.  CSP is also adjusted for 
background mortality, as patients may have died before symptomatic presentation.  The frequency of 
the various treatment strategies and associated unit costs is reported in Table 3. For the symptomatic 
group patients are assumed to present at a stage distribution that matches the national average,[23] 
the stage specific unit treatment cost is estimated using the stage specific averages from the CT arm 
of the model given in Table 3. 
[Table 3 here] 
Benefits 
As discussed earlier the benefits of screen-detection versus symptomatic presentation are estimated 
by adapting the survival model referenced and applied by the UKLS study.[19]  
The estimation of benefit uses actuarial tables which estimate the probability of dying in any given 
year for a number of different states of being (for this model gender and presence and stage of 
cancer).[23]  Estimates of the life expectancy of each true positive lung cancer case are made at an 
individual patient level assuming both the cancer was diagnosed using the screening test, and that if 
the screening test had not been available the cancer would have presented symptomatically at a later 
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date.  An estimate of the stage specific time between the identification at screening and symptomatic 
presentation is incorporated to account for lead time bias.   
This approach can be characterised using Figure 1, reproduced from Whynes.[19]  It shows the 
estimated relationship between survival curves (along axes of age (A) and number who survive (N)) of 
ƚŚƌĞĞĐŽŚŽƌƚƐ P  ‘ŶŽƌŵĂů ?survival curve based on life expectancy of the overall population; screened 
cohort; symptomatic cohort. Survival of the symptomatic cohort beyond the point of diagnosis at ASP 
decays rapidly compared to both the normal cohort and the screened cohort which is diagnosed (and 
therefore treated) at an earlier point ACT.         
Using this approach it is therefore possible to estimate the LY gains from screening by considering the 
difference between the areas under the two lung cancer survival curves (screened and symptomatic).  
Doing so at a patient level, as done in our study and in the UKLS analysis (Whynes originally took a 
single cohort approach), allows for the adjustment of the model to differences in gender, the age of 
presentation, and the stage of presentation. The incremental LYs are then adjusted for the expected 
quality of life experienced by the patient.   
 
[Figure 1 here] 
 
To account for the higher level of mortality associated with deprivation in Manchester compared to 
the UK, we calculated the survival curves specific to Manchester residents. For each individual 
diagnosed with screen-detected lung cancer we constructed a statistical table for (a) symptomatic 
presentation, and (b) CT-screened presentation, factoring in published stage and gender specific 1 
year and 5 year survival rates.  The UKLS approach to stage specific survival, using evidence from the 
literature, is used to inform the screen detected survival rates, and updated estimates from the Office 
for National Statistics (ONS) for the symptomatic presentation curves (the original UKLS analysis used 
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an older version of the same source).  These values are reported in Table 4.  Stage 4 cancers are 
assumed to have the same survival rate as observed in the symptomatic presentation group whether 
diagnosed symptomatically or by screening.  This implies no health benefit in identifying patients at 
stage 4 through screening.  An exponential decay function is fitted to the two time points for each 
stage of cancer.  
[Table 4 here] 
 
In addition to modelling the difference in survival time given symptomatic or screen detection the 
model takes account of the lead time of each stage of disease, i.e. the time between identification at 
screening and any symptomatic presentation.  While some authors have sought to estimate the lead 
time precisely,[24] these estimates are, due to the unobservable naturĞŽĨĂƉĂƚŝĞŶƚ ?ƐůĞĂĚƚŝŵĞ ?ŚŝŐŚůǇ
assumption based and in need of further development.  This model takes the same approach as used 
in UKLS that lead times can be estimated from the difference in the ages between symptomatic 
presentation and the screen detected programme (roughly 3, 2, 1, and 0 years for stage 1 to 4).  To 
account for the significant uncertainty in these estimates the UKLS approach incorporated into the 
model lead times twice these observed rates (so 6, 4, 2, and 0).  This assumption biases against CT 
screening (i.e. are conservative) as shorter lead times imply that lung cancer progresses more quickly 
between Stages 1 and 4, making the benefits of early stage diagnosis greater as without it lives and 
life years are lost very quickly.   
Finally, to adjust for ƉĂƚŝĞŶƚƐ ? quality of life after the development of cancer we adjust the estimated 
life years gained by an expected quality of life score, consistent with the approach taken by UKLS.  
Adjusting the life years by a quality of life score indicative of a cancer sufferer would risk biasing the 
benefit of diagnosing and treating patients earlier as many survive cancer and those who do not would 
experience the quality of life implications whether they were diagnosed through screening or 
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symptomatically.  Therefore a quality of life adjustment indicative of an age adjusted typical person 
was used, 0.7472 as used in UKLS from estimates by Kind et al.[25]  
 
Results 
Bringing the Cost Elements Together 
/ŶƚŚĞŵĞƚŚŽĚƐƐĞĐƚŝŽŶǁĞĚĞĨŝŶĞĚƚŚĞĨŽƌŵƵůĂ “E^A?EW ?/TPA?d ?A?E& ?/FP ?ĂƐĚĞĨŝŶŝŶŐƚŚĞŝŶĐƌĞŵĞŶƚĂů
cost of the screening programme.  Using the methods outlined this resolves into: 
Total adĚŝƚŝŽŶĂůĐŽƐƚA? ? ? ? ? ? ? ? ?A? ? ? ? ? ? ? ? ? ?A? ? ? ? £788 
 = £566,013 + £66,323 + £30,740 
 = £663,076 
This shows that the cost of conducting the screen, £566,013, was the largest cost component, 
compared to the cost of diagnosing and net additional cost of treating the true positives, £66,323, and 
of diagnosing false positives, £30,740.   
Health Benefits of the Screening Programme 
Based on the survival assumptions described above, we find that the total undiscounted Life Years 
gained through screening are estimated to be 128.24 LYs, 88.13 LYs when discounting is applied.  Table 
5 shows the number of people diagnosed as true positives in the trial, according to stage and gender, 
alongside the average estimate LY gains (undiscounted) as a result of the screening programme.  When 
discounting rules are applied the average estimated LYs gained across the 42 true positive patients is 
2.10. 
[Table 5 here] 
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The table highlights the significant benefits of identifying patients earlier, with an average gain of up 
to 4.19 years, significant considering the average age of this population was 67.6.  It also highlights 
the importance of early diagnosis, with a large decrease in expected gains as the stage moves from 1 
to 2 or 3 and then to 4, where there is no gain expected from screening.    
Adjusting the LY gained by ƉĂƚŝĞŶƚƐ ?ĞǆƉĞĐƚĞĚquality of life results in a QALY gain of 65.85. 
Combining the Costs and Benefits 
Conventionally the result of a cost-effectiveness analysis is reported as the incremental cost-
effectiveness ratio (ICER) in terms of the additional cost of an intervention and in terms of the 
ĂĚĚŝƚŝŽŶĂůŐĂŝŶŝŶY>zƐ ?dŚĞƌĞƐƵůƚĂŶƚ/ZŝƐƚŚĞŶĐŽŵƉĂƌĞĚƚŽĂ ‘ĐŽƐƚ-ĞĨĨĞĐƚŝǀĞŶĞƐƐƚŚƌĞƐŚŽůĚ ?ǁŚŝĐŚ
is used to determine the point at which a new intervention would represent a worthwhile use of finite 
NHS resources.  In the UK a threshold value of £20,000 to £30,000/QALY is most often used, due to its 
use by the National Institute for Health and Care Excellence (NICE) in their decision making process.  
However, recent quantitative research has argued that this value should be closer to 
£13,000/QALY.[26]  The analysis described in this paper results in an ICER of £10,069/QALY, below any 
of the threshold values considered appropriate, and therefore suggesting that, under the base-case 
assumptions, the Manchester pilot represents a cost-effective use of NHS resources.  
Uncertainty analyses 
While the base-case analysis represents a best estimate of the expected lifetime costs and benefits of 
the Manchester LHC pilot, there are inevitably areas of uncertainty that, to some extent can be 
explored through uncertainty analysis.  We conducted two scenario analyses to explore the sensitivity 
of the results to changes in the base case assumptions, relating to the modelled survival times and the 
lead times. 
As with the UKLS approach we modelled the mortality rates of CT and symptomatically presenting 
patients using a decay function applied to data on one and 5 year survival from the literature (for CT) 
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and the ONS (for symptomatic presentation).  The nature of the informative data makes traditional 
probabilistic sensitivity analysis difficult as we have no robust estimates of the standard error.[27]  As 
a result, we explored the sensitivity of the model to the CT mortality rates by adjusting the estimated 
time dependent rates, using a hazard ratio.  This found that applying a hazard ratio of 0.5 (i.e. reducing 
the annual mortality rate for CT detected patients by half) reduced the ICER to £5,801/QALY.  Similarly 
a hazard ratio of 1.5 resulted in an ICER of £26,837.  
In addition, a scenario analysis in which we weakened the bias against screening by reducing the lead 
times estimates to 3, 2, 1 and 0 years for stage 1-4 respectively was conducted. These values most 
closely reflect the point estimates that were considered most likely in the UKLS model, but which were 
adjusted in the base case to ensure a conservative analysis.  This scenario reduces the ICER to 
£5,579/QALY as the benefits of diagnosing a lung cancer earlier increase. This is due to the increased 
speed at which the cancer is assumed to develop through the stages and therefore the risk of mortality 
under a reliance on symptomatic presentation.  In a related scenario we identified that the lead times 
would need to increase to 8.0, 5.4 and 2.7 for the screening programme to no longer be cost effective 
(assuming the same relative size of the lead times). 
Discussion 
This economic evaluation of the Manchester Lung Health Check pilot found it to be a cost-effective 
use of NHS resources if the significant long-term benefits both to patient health and NHS expenditure 
were considered.  A base-case ICER of £10,069/QALY was estimated, lower than both the conventional 
cost-effectiveness threshold used by NICE, and the recently estimated value of the threshold by 
Claxton et al. of £13,000/QALY.[26] This is comparable to the findings of the UKLS trial analysis which 
estimated an ICER of £8,466/QALY.  The primary difference between this study and UKLS is the use of 
mobile scanners over fixed, hospital based, units.  In this trial the cost per reported CT scan was £286, 
compared to an estimated cost of using a fixed unit of £232 (CT of up to three areas with contrast plus 
an MDT meeting from the NHS Reference Costs)[21], a difference of £54 per scan.  However, while 
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hospital based screening is cheaper per scan it is likely that many patients who benefitted from this 
screen would have been put off from attending a hospital setting.  As a result, it is not reasonable to 
assume that the results of this trial can be directly transferred to a hospital setting at a reduced cost. 
The UKLS analysis additionally reported 95% confidence intervals around the cost and LYs by assuming 
normality and re-estimated the net cost using Monte-Carlo simulations, resulting in a confidence 
interval of £362,564 to £769,309 around their mean estimate of £565,498, and 2.6 to 3.9 LYs around 
a mean of 3.3 LYs.  Combining these gave a 95% confidence interval for UKLS of £5,542 to 
£12,569/QALY around a mean of £8,466/QALY. 
The methodology and characterisation of the normal distribution and the parameters incorporated 
was, nevertheless, unclear making replication impossible.  Attempts were made to conduct a similar 
analysis through the Monte Carlo resampling of triangular distributions (considered more practicable 
due to their facilitation of a minimum and maximum), which resulted in a 95% confidence interval of 
£8,407 to £12,002/QALY. 
We consider the estimated confidence intervals reported in this study and UKLS, give a misleading 
indication of the level of uncertainty present in the analysis.  This is because the UKLS method, and 
indeed any approach based on a life table methodology, is unlikely to be able to fully incorporate the 
parameter uncertainty evident in the underlying model.  This is due to the informative life tables 
typically only reporting point estimates of e.g. mortality risk, making any informative distribution 
applied purely speculative.  Furthermore, while statistical methods such as bootstrapping are available 
to consider the impact of the screening programme identifying a different mix of patients, this can 
only ever be informed within the confines of the pilot or trial findings, which in this case are arguably 
too limited in size and scope to be informative about the true level of uncertainty.  Therefore, while it 
is possible to attach confidence intervals, we do not consider that such an approach is informative of 
the true level of uncertainty, risking giving false confidence in a point estimate.  In reality the cost-
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effectiveness of such programmes, especially at relatively small scale, is hugely uncertain and 
dependent on many factors which, given the current level of research, are not robustly quantifiable.  
The main strength of this analysis stems from its replication of the UKLS study, not only imbuing the 
benefits of the peer reviewed method by Whynes but allowing for the direct comparison of the results 
of the two studies.  We also extended the scenario analyses conducted in UKLS by exploring the impact 
of changes to the modelled mortality rate, finding the result to be sensitive. 
However, as with the UKLS study this analysis has a number of weaknesses.  The reductive nature of 
the model, primarily considering the survival benefit of earlier stage lung cancer diagnosis with a 
quality of life adjustment for the life years gained with screening, implies a limited definition of benefit 
of the programme, failing to reflect the potential benefits of other factors including COPD diagnosis, 
or smoking cessation (advice given to all attendees).  Furthermore, the analysis is limited by the scale 
and scope of the pilot, failing to reflect the impact of the screening past the first follow up at 3 months 
or whether a different screening criteria or approach in the same population would be more cost-
effective. 
 
Conclusions 
This analysis applied the method devised by Whynes and used in the UKLS analysis to estimate the 
cost-effectiveness of the Manchester Lung Health Check pilot, finding it cost-effective at an ICER of 
£10,069/QALY.  This is an important finding as it presents another validation of the cost-effectiveness 
of lung cancer screening but in a different setting and carried out differently to the UKLS.   
Cost effectiveness, determined by the cost of screening and treatment and the benefits derived 
through increased longevity, is underestimated in the model through the conservative approach to 
lead times and exclusion of numerous health benefits beyond lung cancer diagnosis.  Potential 
overestimates may emerge if survival rates of screened cases are lower than projected; this data 
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would become available in the future through longitudinal analysis of mortality among the screened 
cohort.   
Further research is needed not only to address the limitations of this analytical method and 
informative data, but also to go beyond the question of is screening cost-effective, to how can it be 
designed to be the most cost-effective, realising the greatest population health gain while remaining 
an effective use of limited NHS resources.  These questions will begin to be addressed through the 
continued analysis of findings from the NELSON trial, the forthcoming Yorkshire Lung Screening Trial 
and additional NHS commissioned screening in Manchester. 
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Figure 1: survival curves for the normal, screen, and symptomatically detected cancers, reproduced from Whynes[19] 
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Table 1: Cost of conducting the screening programme 
Cost Number of people Unit cost Total cost 
Recruitment  ? 
invitation letters  
16,402  £2  £37,527  
Lung Health Checks  2,613 (2,541 of whom 
consented for further 
data collection) 
£33  £86,425  
Initial LDCT scan & 
reporting  
1,384  £286  £395,511  
3 month LDCT scan & 
reporting  
191  £244  £46,550  
Total   £566,013 
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Table 2: Diagnostic workup costs in the true and false positive groups 
Test Frequency Unit cost 
True Positives 
(n=42) 
False Positives 
(n=39) 
Spiro/DLCO  34 23 95.04 
Blood Sample  35 18 2.00 
PET-CT  35 17 720.00 
Percutaneous Lung 
biopsy  
21 4 706.21 
Staging EBUS  10 3 1,300.00 
Diagnostic EBUS  1 0 1,300.00 
Radial EBUS 1.7mm  3 0 650.19 
Autofluorescence 
bronchoscopy  
2 9 650.19 
Other Sampling 
Technique  
4 0 706.21 
Echocardiogram  4 0 72.45 
CPET  2 0 300.00 
Other radiology  12 6 
 
616.93 
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Table 3: Frequency of treatment and unit cost in the true positive group 
 
 
Surgery 
only 
Surgery & 
Chemo 
Chemo only Radio only 
Chemo & 
radio 
Follow Up Palliative 
No 
Treatment 
N
u
m
b
e
r 
o
f 
st
a
g
e
 a
n
d
 
tr
e
a
tm
e
n
t 
in
te
rv
e
n
ti
o
n
 
Stage 1 21 0 0 3 0 26 0 2 
Stage 2 1 1 1 3 1 7 1 0 
Stage 3 0 3 0 0 1 4 0 0 
Stage 4 0 0 2 1 1 5 4 1 
Total 22 4 3 7 3 42 5 3 
C
o
st
 p
e
r 
tr
e
a
tm
e
n
t 
ca
te
g
o
ry
[2
2
] 
Stage 1 £5,359 £8,988 £3,629 £6,296 £9,925 £1,720 £3,581 £0 
Stage 2 £5,359 £8,988 £3,629 £2,840 £6,469 £1,720 £3,581 £0 
Stage 3 £5,359 £8,988 £3,629 £2,390 £6,019 £1,720 £3,581 £0 
Stage 4 £1,645 £5,274 £5,699 £1,940 £7,639 £1,720 £3,581 £0 
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Table 4: Survival rates used in the model 
 Male survival Female survival 
Stage 1 year 5 year 1 year  5 year 
Symptomatic presentation (ONS) 
Stage 1 or later 34% 11% 40% 15% 
Stage 2 or later 27% 6% 31% 8% 
Stage 3 or later 23% 4% 26% 5% 
Screen detected (UKLS) 
Stage 1 90% 70% 90% 70% 
Stage 2 75% 40% 75% 40% 
Stage 3  55% 22% 55% 22% 
Both - Stage 4 23% 4% 26% 5% 
 
 
Table 5: Stage distribution and estimated LY gains (undiscounted) from screening 
Gender Stage 1 Stage 2 Stage 3 Stage 4 All 
Female  19 (4.10) 1 (2.04) 1 (1.90) 3 (0) 24 (3.41) 
Male  7 (4.44) 6 (1.78) 3 (1.52) 2 (0) 18 (2.57) 
All  26 (4.19) 7 (1.82) 4 (1.61) 5 (0) 42 (3.05) 
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